Physicochemical Properties
| CAS # | 2827065-29-0 |
| PubChem CID | 165412756 |
| Appearance | Typically exists as solid at room temperature |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 3 |
| Heavy Atom Count | 33 |
| Complexity | 649 |
| Defined Atom Stereocenter Count | 0 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | IC50: 2.8 μM (A549 cells)[1] |
| ln Vitro | When coupled with 13da and mrBIQ 13da/14da, antitumor agent-75 (14da) exhibits a highly selective cytotoxic action against human lung adenocarcinoma (cell line A549), with an IC50 value of 2.8 μM[1]. In A549 cells, antitumor agent-75 (1, 5, 25, 50, 100μM; 0-48 h) (mriBIQ 13da/14da) exhibits cytotoxicity[1]. The mechanism of antitumor agent-75 (1, 2.5, and 5 μM; 12 h) (mriBIQ 13da/ 14da)'s lethal action on A549 cells may be linked to the induction of mithochondrial apoptosis, suppression of DNA synthesis, and termination of the cell cycle in phase S[1]. In A549 cells, antitumor agent-75 (1, 2.5, and 5 μM) causes a rise in reactive oxygen species (ROS) and mitochondrial death. |
| Cell Assay |
Cell Cytotoxicity Assay[1] Cell Types: seven cancer cell lines and WI38 (the Normal Human Fetal Lung Fibroblast line) Tested Tested Concentrations: 1 -100 μM Incubation Duration: Experimental Results: demonstrated greater activity against most of the cancer lines and normal human cell lines. Cell Proliferation Assay[1] Cell Types: A549 Cell Tested Tested Concentrations: 1, 5, 25, 50, 100 μM Incubation Duration: 0 -48 h Experimental Results: Lead to a sharp decrease the presence of mriBIQ 13da/14da at concentrations close to the IC50 values in the rate of cell division. Cell Cycle Analysis[1] Cell Types: A549 cells Tested Tested Concentrations: 1, 2.5, and 5 μM Incubation Duration: 12 h Experimental Results: Increased the number of cells in the S-phase with mnBIQ 13da/14da at concentrations of 1, 2.5, and 5 μM at 49.0%, 66.3%, and 68.0%, respectively. Apoptosis Analysis[1] Cell Types: A549 cells Tested Tested Concentrations: 1, 2.5 and 5 μM Incubation Duration: Experimental Results: (mrBIQ 13da/14da) Induced mitochondrial apoptosis in A549 cells. |
| References |
[1]. Synthesis of Morpholine‑, Piperidine‑, and N‑Substituted Piperazine-Coupled 2‑(Benzimidazol-2-yl)-3-arylquinoxalines as. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |